LDS/Medical Tests/CNBP Genetic Analysis for Myotonic Dystrophy, Type II (DM2)

CNBP Genetic Analysis for Myotonic Dystrophy, Type II (DM2)

The CNBP gene (also known as ZNF9) is located in long (q) arm of chromosome 3 at position 21.3 and encodes cellular nucleic acid-binding protein or CCHC-type zinc finger nucleic acid binding protein. This protein contains seven zinc finger domains and is thought to bind to specific sites on DNA and RNA. The CNBP protein is necessary for normal embryonic development and is found in many tissues, but most abundant in heart and skeletal muscles. Intron one of the CNBP gene contains a complex repeat motif: (TG)n(TCTG)n(CCTG)n and all three repeat tracts are present in normal alleles. Each repeat tract can vary in length although the overall length of the repeat is normally 11-26 tetranucleotides in length.

Expansion of CCTG in CNBP gene is associated with myotonic dystrophy type II (DM2). DM2 is an autosomal dominant disorder caused by an expansion of the CCTG tetranucleotide repeat within the CNBP gene. The three repeating units (TG, TCTG, CCTG) within this motif are all highly variable in both individuals with DM2 and the general population. The CCTG repeat is the only repeat that expands to pathogenic lengths, although the highly polymorphic TG and TCTG repeats contribute to the overall length of the expansion. The boundary between stable and unstable alleles appears to be 30 tetranucleotide repeats. Premutation alleles have approximately 30-50 repeats, and pathogenic genes contain from 75-11,000 repeats (average 5000).

Myotonic dystrophies are multisystem disorders that affect smooth and skeletal muscle and are one of the most common forms of muscular dystrophy. DM2 typically presents in the third decade or later with myotonia and muscle weakness or stiffness, but may also include generalized proximal weakness, cardiac conduction defects, posterior subcapsular cataracts, insulin-insensitivity, or testicular failure. Histological findings include atrophic muscle fibers with pyknotic nuclei and marked proliferation of fibers with central nuclei. DM2 affects at least 1 in 8,000 people worldwide.

  • Diagnosis of myotonic dystrophy, type II
  • To differentiate myotonic dystrophy, type II from type I and other muscle wasting diseases
  • Prenatal screening for pregnancies at increased risk and preimplantation genetic testing in an affected family member identified with the CCTG repeat expansion

Any increase in CCTG repeat above 57 might indicate myotonic dystrophy, type II

CCTG repeats in Myotonic dystrophy, type II

  • Pathogenic. ~75-11,000 CCTG repeats
  • Smallest reported repeats: 55-57
  • Largest reported repeats: 11000

Normal: <30 CCTG repeats

Polymerase Chain Reaction, Southern blot analysis (for larger expansions), Next Generation Sequencing.

Whole blood (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Genetic testing for type-1 myotonic dystrophy (DMPK) CTG Expansion, Muscle biopsy, Serum CK concentration, Electromyography (EMG), serum protein electrophoresis, glucose tolerance test, slit lamp examination, echocardiography (ECG),
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login